ID   YP-MEL
AC   CVCL_L217
DR   Wikidata; Q54995472
RX   PubMed=7520166;
RX   PubMed=9290701;
CC   Population: Japanese.
CC   Doubling time: 41 hours (PubMed=7520166).
CC   Derived from site: Metastatic; Brain; UBERON=UBERON_0000955.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   4Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 29-06-23; Version: 8
//
RX   PubMed=7520166; DOI=10.1016/S0344-0338(11)80709-0;
RA   Nagashima Y., Miyagi Y., Aoki I., Funabiki T., Ikuta K., Umeda M.,
RA   Kuchino Y., Misugi K.;
RT   "Establishment and characterization of a malignant melanoma cell line
RT   (YP-MEL) derived from a patient with neurocutaneous melanosis.";
RL   Pathol. Res. Pract. 190:178-185(1994).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//